Russia's COVID-19 vaccine successfully completes first phase of human clinical trials


A group of 18 volunteers was involved in the first stage of vaccine research at Sechenov University. Among others, 15 candidates are in the first phase of clinical trials, 10 are in Phase II, and three candidates are in the third phase of the clinical trials, the report added.

According to a report by The Week, the vaccine is still in the first stage which has been split into two halves. There are several hurdles to be passed in the search for any vaccine.

Bharat Biotech had stated that it is working to develop an initial capacity of 200 million vials of the vaccine. The person who gets the booster form of the vaccine is guaranteed to get protection against the virus for two years or more. The document of the World Health Organisation on COID-19 vaccine also states the same.

Drugmakers partnered with the US government are on track to begin actively manufacturing a vaccine for COVID-19 by the end of the summer, a senior administration official said on Monday.

M - US health officials and drugmakers expect to start producing potential coronavirus vaccine doses by the end of the summer, a senior administration official said Monday, CNBC reported. Initially, some participants reported headaches and high body temperature. During the trials, 18 volunteers from the armed forces had been administered the vaccine.

The COVID-19 Prevention Network, which is funded by the National Institute of Health, launched a website for people in the United States looking to volunteer for clinical trials as a few vaccines are ready for phase 3. Therefore, it would not be wrong to say that Russia's claim about coronavirus vaccine is not completely correct.

On May 19, Moderna, an American biotechnology company based in Cambridge, Massachusetts, announced that its experimental vaccine had registered positive results after clinical trials. Every country and every lab is taking a different approach to finding the right solution to stop the virus.

Big Pharma's vaccine candidates were earlier slated to reach any fruition only by end-2020., with large-scale clinical trials to take place post regulatory approval in July.

The milestone follows months of pre-clinical testing by UQ, since the vaccine candidate was selected as the university's most promising in mid-February.

Mr Rajoelina has been promoting the brew for export, saying it is the country's "green gold which will change history".